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A New Multiantigen Immunoassay for the Quantification of IgG Antibodies to
Capsular Polysaccharides of Streptococcus pneumoniae
Felix Roth, Thomas Burkart, and Kathrin Mu¨hlemann Institute of Medical Microbiology, University of Berne,
Berne, Switzerland
A new nitrocellulose-based solid-phase multiantigen immunoassay (MAIA) for the detection of
serum antibodies to Streptococcus pneumoniae capsular polysaccharides (PPSs) is presented. Evalua-
tion with human sera showed that the MAIA test is reproducible, sensitive, and specific. It correlated
well with a conventional ELISA method. The multiantigen strip system allowed quantification of
antibodies against several PPS serotypes simultaneously and with a minimal amount of serum
specimen. The presented solid-phase immunoassay for the quantification of anti-PPS antibodies
seems to be a superior and attractive alternative to currently used ELISA tests and offers possibilities
for standardization.
and was obtained from the Blood Donor Center (St. Gallen, Swit-Streptococcus pneumoniae is a predominant causative agent
zerland).for life-threatening invasive diseases, such as meningitis, pneumo-
A standard serum pool (Food and Drug Administration [FDA]nia, and sepsis [1, 2]. Recent emergence of antibiotic-resistant
lot 89-SF) consisting of sera from 17 healthy adults vaccinatedstrains stresses the need for safe and efficacious vaccines [3].
with the 23-valent pneumococcal polysaccharide vaccine (vacci-To evaluate the efficacy of existing and newly produced poly-
nated pool) was provided by C. Frasch (Laboratory of Bacterial
saccharide vaccines against S. pneumoniae, valid and reproducible
Polysaccharides, Center for Biologics Evaluation and Research,
methods for the measurement of serotype-specific antibodies are FDA, Bethesda, MD). The vaccinated pool has IgG levels defined
needed [4]. Currently used ELISA techniques have some short- for PPS serotypes 19F (13 mg/mL), 14 (27.8 mg/mL), 6B (16.9
comings. Their reproducibility is limited by poor and inconsistent mg/mL), 1 (6.3 mg/mL), 9V (6.9 mg/mL), 4 (4.1 mg/mL), and 18C
binding of capsular polysaccharide (PPS) to plastic surfaces [4, (4.5 mg/mL).
5]. Contamination of PPS preparations with cell wall polysaccha- For further evaluation of the test, 101 consecutive sera from
umbilical cord blood (cord sera) submitted to the diagnostic divi-rides of S. pneumoniae may lead to nonspecific binding of anti-
sion of our institute between 1991 and 1993 were used. Sera frombodies [6]. Also, ELISAs require separate tests for each serotype
11 patients vaccinated because of splenectomy were examined.investigated. Standardization of the ELISA for the comparability
Paired sera taken before (range, 2 weeks to 30 months) and afterof results within and between laboratories has not been possible
(range, 2 weeks to 3 years) vaccination were available from 6so far [4]. Despite claims that RIA is not affected by the presence
patients, and single sera after vaccination (range, 1–13 months)of antibody to CPS [7, 8], several investigators have used a variety
from 5 additional patients. In addition, antibodies were measured
of approaches in vitro [4–6] and in experimental animals [6, 9]
in a patient with invasive infection due to S. pneumoniae serotype
to show that such antibody is detected. However, those methods 9N. All sera were stored at 0207C.
involve handling of radioactivity and also pose problems with Antigens. PPSs of serotypes 19F, 14, 6B, 1, 3, 7F, 9N, 9V, 4,
standardization [4]. and 18C (Danish designation) were obtained from the American
A novel multiantigen immunoassay (MAIA) has been used Type Culture Collection (Rockville, MD). These serotypes are
to detect antibodies against protein and lipid antigens derived contained in the currently used 23-valent polysaccharide vaccine
from Mycobacterium tuberculosis cells (Roth F, Riniker F, and are among the most prevalent serotypes circulating in Switzer-
land [10]. Cell wall polysaccharide preparations (CPS) were pur-Burkart T, unpublished data). This nitrocellulose-based, rapid,
chased from Statens Seruminstitut (Copenhagen).sensitive, solid-phase immunoassay system offers a wide appli-
ELISA. IgG antibodies to PPSs of serotypes 14 and 19F werecation potential. Here we describe the adaptation of this tech-
measured in a modified ELISA system as described by Musher etnique to quantify IgG serum antibodies against PPSs of various
al. [11]. Briefly, 96-well microtiter plates (Maxisorb; Nunc,S. pneumoniae serotypes.
Roskilde, Denmark) were coated for 5 h at 377C with 110 mL of
a solution of 10 mg of PPS or CPS/mL in PBS, pH 7.4, per well.Material and Methods
Excess antigen was removed by 5 washes with PBS. All sera
Serum samples. The donor pool was 100 sera from healthy diluted 1:50 with PBS–0.05% Tween 20 (PBS-Tween) were pre-
adult blood donors of unknown pneumococcal vaccination status adsorbed with 10 mg of CPS/mL for 30 min. Preadsorbed vacci-
nated pool was used in seven 2-fold dilutions starting at 1:400.
Patient sera were analyzed at a dilution of 1:200. Preadsorbed sera
Received 9 October 1996; revised 3 March 1997. (100 mL) were incubated for 120 min, followed by 5 washes with
Reprints or correspondence: Felix Roth, Institute of Medical Microbiology, PBS-Tween. Then, 100 mL of monoclonal mouse anti-human IgG–
University of Berne, Friedbu¨hlstrasse 51, CH-3010 Berne, Switzerland.
HRPO conjugate (Hybridoma Reagent Laboratory, Baltimore) di-
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o-phenylenediamine and 4 mL of 3% H2O2/mL in 0.1 M citric loss (96% for PPS 14 and 85% for PPS 19F) occurred during
acid–phosphate buffer, pH 5.0) was added and reacted in the dark. the first incubation, the blocking step (data not shown). Dilution
The enzyme reaction was stopped after 15 min with 100 mL of 2 curves of the vaccinated pool for IgG antibodies against PPS
M H2SO4 per well. serotypes 19F, 14, 6B, 1, 9V, 4, and 18C were close to linear for
All incubations were done at room temperature (RT). For all all serotypes over a broad antibody dilution range (correlation
buffers and dilutions, endotoxin-free, sterile, double-distilled H2O coefficients, .91–.96). Sensitivity was at least 0.1 mg of IgG/
was used. Optical densities (OD) were measured at 490 nm
mL for all serotypes. Specificity was excellent, as demonstrated(Thermo Max; Molecular Devices, Menlo Park, CA). Background
by antibody inhibition with serotype-specific PPS (figure 1A).signals were obtained from wells with PBS-Tween instead of se-
IgG antibodies to 10 different PPS serotypes were measuredrum. Preadsorption efficacy was controlled by testing the vacci-
in 101 cord sera. As expected, the mean IgG titers of cord seranated pool on CPS-coated wells. Logarithmically transformed OD
values of the vaccinated pool dilutions were used to define a stan- were considerably lower than those in the vaccinated pool and
dard curve. Sera with net OD values outside the range from 0.1 slightly but consistently lower than those in the donor pool
to 0.9 were retested using other serum dilutions. (data not shown).
MAIA. IgG antibodies to PPS of serotypes 19F, 14, 6B, 1, 3, Reproducibility of the MAIA was excellent. For example,
7F, 9N, 9V, 4, and 18C were tested using a modified MAIA system coefficients of variation for up to six separate assays, performed
(Roth F, Riniker F, Burkart T, unpublished data) [11]. PPS antigen on the same or different days, on the donor pool were 1.73%
(100 mg/mL in 0.9% [wt/vol] NaCl) was sprayed as parallel bands
for PPS 19F, 2.26% for PPS 14, 2.18% for PPS 6B, 0.43% for
(1 mL/cm each) on a nitrocellulose membrane (BA 85, 0.45 mm
PPS 1, 2.75% for PPS 9V, 1.41% for PPS 4, and 1.53% forpore size; Schleicher & Schuell, Feldbach, Switzerland) with an
PPS 18C.applicator (Linomat III; Camag, Muttenz, Switzerland). Air-dried
MAIA was compared to ELISA for serotypes 14 and 19Fsheets were cut into 3-mm strips (Accutran; Schleicher & Schuell)
(figure 2). IgG levels obtained from both tests for the 101 cordand stored dry in the dark at RT.
All incubations were performed in 8-channel transfer plates sera correlated well (serotype 14: r  .70; serotype 19F: r 
(Inotech, Wohlen, Switzerland) at RT under moderate agitation. .68). The slope of the curve was 1.09 for serotype 14 and
To block nonspecific binding, the strips were incubated with 1 mL 1.12 for serotype 19F. However, the ELISA gave slightly but
of 0.5% (wt/vol) casein (Sigma, St.Louis) in TRIS-buffered saline consistently higher IgG values than the MAIA. This discrep-
(Cas-TBS), pH 7.4, for 30 min. In the meantime, 1 mL of serum ancy was accentuated in the very low and very high antibody
sample and controls diluted 1:100 with Cas-TBS were preadsorbed level ranges.
with 0.1 mg of CPS for 30 min. The strips were exposed for 60
Figure 1B demonstrates the antibody response to pneumo-
min to the preadsorbed sera (dilution 1:100). After 3 washes with
coccal vaccination (patients 1–11). Antibody titers rose by⁄2-1 mL of Cas-TBS for 10 min, strips were incubated with 50 ng/
fold against five to nine serotypes within 2 weeks to 3 monthsmL alkaline phosphatase–conjugated anti-human IgG (Sigma) for
(figure 1B, patients 1–5). A ⁄2-fold decrease of the antibody90 min, followed by 3 wash steps. Incubation with 5-bromo-4-
titer against serotypes 3 and 18C was observed in patient 6 atchloroindoxylphosphate and nitroblue tetrazolium led to the gener-
ation of a colored precipitate (figure 1) [13]. 3 years after vaccination. Antibody levels in patients 7–11
The insoluble dye product was quantified at 546 nm with a were comparable to those in the vaccinated pool and higher
densitometer (CD 60; Desaga, Heidelberg, Germany). Net OD than those in the donor pool for most serotypes. Patient 14
values were obtained after subtraction of the background (blank) mounted a specific antibody response to serotype 9N upon
values on the film (performing the assay with PBS instead of serum invasive infection.
never gave higher background signals). Specific IgG levels of the
sera in micrograms per milliliter were calculated, with reference
to the IgG values of the vaccinated pool. Discussion
To study the adsorption of antigen to nitrocellulose, PPS 14 and
Poor binding of polysaccharides to polystyrene affects thePPS 19F were labeled with 125I (120 mCi/100 mL; 4.44 1 106 Bq)
performance of the most commonly used ELISA [4, 5]. Theusing a commercial radioiodination kit (Bio-Rad, Richmond, CA)
excellent reproducibility of the MAIA suggests that nitrocellu-[14]. Antigen retention was monitored over the entire assay, except
for the color reaction step, using blood donor aliquots and noncon- lose might have better adsorption qualities for polysaccharides
jugated anti-human IgG. Adherent 125I-labeled antigen was mea- than plastic surfaces. Loss of PPS occurred only during the
sured by exposing nitrocellulose strips for 16 h to x-ray film and first incubation step of the MAIA (probably due to nonadsorbed
quantifying signals by densitometry at 546 nm. antigen). Similar studies on the amount of bound PPS during
Specificity of the MAIA was evaluated by antibody inhibition. the ELISA cannot be performed as yet, and therefore a compari-
After preadsorption with CPS, the vaccinated pool was incubated son is not possible. The generation of insoluble reaction prod-
for 1 h with 2 mg/mL serotype-specific polysaccharides.
ucts in the MAIA might have further contributed to enhanced
reproducibility.
Results obtained by MAIA correlated well with those fromResults
ELISA. However, the ELISA measured slightly but consis-
tently higher antibody concentrations. The reason for this dis-Overall retention of 125I-labeled polysaccharides on nitrocel-
lulose was 53% for PPS 14 and 40% for PPS 19F. The major crepancy is not clear, but the remarkably linear dilution curves
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Figure 1. Specificity of MAIA assay in antibody inhibition experiments (A) and antibody response to pneumococcal vaccination or invasive
infection (B). B, Lanes 1–6, patients before (b) and after (a) vaccination; 7–11, patients after vaccination; 12, donor pool; 13, vaccinated pool
(FDA lot 89-SF); 14, patient at time of infection (c) with serotype 9N and 6 months later (d).
over a broad range of antibody levels for various serotypes niae serotypes simultaneously and with a minimal amount of
serum. For example, 1 person can test a large number of seraof S. pneumoniae indicate that MAIA is a sensitive assay.
Differences between the two tests might also be at least partly against 12 serotypes in 1 day. Second, in our laboratory, the
antigen-coated nitrocellulose strips have been stable over atdue to shortcomings of the ELISA.
Contamination of PPS preparations with CPS of S. pneumo- least 1 year. Prepared nitrocellulose strips could be distributed
by one center. This would obviate a special infrastructure (e.g.,niae necessitate the preadsorption of sera for ELISA [6]. This
extends also to MAIA. Recently, Nahm et al. [8] claimed that the Linomat applicator for uniform coating of the polysaccha-
ride) in individual laboratories and it would save time. Mosta modified Farr assay was less affected by CPS contaminations
and more specific than ELISA. However, the Farr test involves importantly, it would enhance comparison of results within and
between laboratories.radioactivity. Also, the study by Nahm et al. [8] demonstrated
that preadsorption of sera for ELISA led to good correlation In conclusion, MAIA seems to have potential as a rapid,
sensitive, specific assay for the quantification of IgG antibodieswith results from the modified Farr assay [8].
The new MAIA has important advantages that existing tests against PPS of S. pneumoniae. The principle of this assay offers
a greater possibility of standardization than do commonly useddo not share. First, the principle of multiantigen-carrying strips
allows determination of antibody levels to various S. pneumo- tests.
Figure 2. Comparison of MAIA and
ELISA for IgG concentrations of antibodies
to S. pneumoniae serotypes 14 and 19F in
101 umbilical cord sera.
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